Buradasınız

Anasayfa » Content

Profilaktik HPV aşıları: güncel yaklaşımlar

Prophylactic HPV vaccines: current approaches

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2010

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
recognition of a strong etiological relationship between infection with high-risk human papillomaviruses and cervical cancer has prompted research to develop and evaluate prophylactic and therapeutic vaccines. One prophylactic quadrivalent vaccine using L1 virus-like particles (VLP) of HPV6, 11, 16 and 18 (Gardasil®) is available on the European market since the end of 2006 and a second bivalent vaccine containing virus-like particles of HPV16 and HPV18 (Cervarix®) is available since 2007. HPV16 and HPV18 cause approximately 43000 cases of cervical cancer each year. Results of the phase-IIb and III trials published thus far demonstrate that the L1 VLP HPV vaccine is safe and well-tolerated. It offers HPV-naive women a very high level of protection when compared to HPV persistent infection and cervical intra-epithelial lesions associated with the types included in the vaccine. HPV vaccination should be offered to girls before onset of sexual activity. Although prophylactic vaccination is likely to provide important future health gains, cervical screening should also be continued.
Bookmark/Search this post with
Abstract (Original Language): 
Yüksek riskli human papilloma virus (HPV) ile servikal kanser arasında sıkı etiyolojik bağlantının olduğunun ortaya konulmasından sonra profilaktik ve tedavi amaçlı aşı bulunması yönünde araştırmalar başlamıştır. HPV 6-11- 16-18’e ait L1 virüs benzeri partikül içeren bir kuadrivalan aşı (Gardasil®) 2006 yılının sonundan itibaren Avrupa ülkelerinde kullanılmaya başlanmıştır ve 2007 yılından itibaren HPV 16 ve 18’e karşı geliştirilen bivalan bir aşı (Cervarix®) piyasaya sürülmüştür. HPV 16 ve 18 her yıl yaklaşık 43000 servikal kanser vakasına sebep olmaktadır. Yayınlanan faz 2b ve faz 3 çalışmaları aşının güvenilir ve iyi tolere edilebilir olduğunu göstermektedir. Bu aşı HPV ile hiç karşılaşmamış bayanlarda, HPV ile persistan enfekte veya belirtilen tiplerde HPV içeren servikal intraepitelyal lezyonu olanlara göre daha iyi koruma sağlamaktadır. HPV aşılaması kızlarda ilk cinsel aktiviteden önce uygulanmalıdır. Profilaktik HPV aşılaması, ileride sağlıklı ve hastalıksız günler öngörse de, servikal tarama yine de yapılmalıdır.
FULL TEXT (PDF): 
PDF icon arastirmax-profilaktik-hpv-asilari-guncel-yaklasimlar.pdf
  • 2
148-156
  • Turkish

REFERENCES

References: 

Kaynaklar
1. Bosch FX, Lorincz AT, Munoz N, Meijer CJ, Shah KV.
The casual relation between human papilloma virus
and cervical cancer. J Clin Pathol 2002; 55: 244-265.
2. Frazer IH. Prevention of cervical cancer trough
papilloma virus vaccination. Nat Rev Immunol 2004; 4:
46-55.
3. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El
Ghissassi F. Carcinogenicity of human papillomaviruses.
Lancet Oncol 2005; 6: 204.
4. Munoz N, Bosch FX, Castellsague X, et al. Epidemiologic
classification of human papillomavirus types associated
with cervical cancer. N Engl J Med 2003; 348: 518-527.
5. Pakin DM, Bray F. Chapter 2: the burden of HPV related
cancer. Vaccine 2006; 24 (Suppl 3): S11-25.
6. Woodman CBJ, Collins SI, Young LS. The nature history
of cervical HPV infection: unresolved issues. Nat Rev
Canad 2007; 7: 11-22.
7. Smith JS, Lindsay L, Hoots B, et al. Human Papillomavirus
type distrubution in invasive cervical cancer and highgrade cervical lesions: a meta–analysis update. Int J
Cancer 2007; 3: 621-632.
8. Amanda T, Alison F. Human papillomavirus (including
vaccines). Obstetr Gynecol Reprod Med 2007; 17:
324-329.
9. Stanley M. Immunobiology of HPV and HPV vaccines.
Gynecol Oncol 2008; 109: 15-21.
10. Kabayashi A, Greenblatt RM, Anastas K, et al. Functional
attributes of mucosal immunity in cervical intra epitelial
neoplasia and effect of HIV infection. Cancer 2004; 64:
6766-6774.
11. Greenstone HL, Nieland JD, de Visser KE, et al. Chimerc
papillomavirus virus-like particules elicit antitumor
immunity aganist the E7 oncoprotein in an HPV
16 tumor model. Proc Natl Acad Sci USA 1998; 95:
1800-1805.
12. Carter JJ, Koutsky LA, Wipf H, et al. The natural history
of human papilloma virus type 16 capsid antibodies
among a cohort of university women. J Infect Dis 1996;
174: 927-936.
13. Villa LL, Costa RLR, Petta CA, et al. Prophylactic
quadrivalent human papillomavirus (types 6, 11,
16, and 18) L1 virus-like particle vaccine in young
women: a randomised double-blind placebo-controlled
multicentre phase II efficacy trial. Lancet Oncol 2005;
6: 271-278.
14. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a
bivalent L1 virus-like particle vaccine in prevention of
infection with human papillomavirus type 16 and 18
in young women: a randomised controlled trial. Lancet
2004; 364: 1757-1765.
15. Koutsky LA, Ault KA, Wheeler CM, et al; Proof of
Principle Study Investigators. Controlled trial of a
human papillomavirus type 16 vaccine. N Engl J Med
2002; 347: 1645-1651.
16. Franco EL, Harper DM. Vaccination against human
papillomavirus infection: a new paradigm in cervical
cancer control. Vaccine 2005; 23: 2388-2394.
17. Kulasingam SL, Myers ER. Potential health and economic
impact of adding a human papillomavirus vaccine to
screening programs. JAMA 2003; 290: 781-789.156 • Haziran 2010 • Gülhane Tıp Derg Dede
18. Steenbergen RD, de Wilde J, Wilting SM, et al. HPVmediated transformation of the anogenital tract. J Clin
Virol 2005; 32 (Suppl 1): S25-S33.
19. Pagluisi SR, Teresa AM. Efficacy and other milestones for
human papillomavirus vaccine introduction. Vaccine
2004; 23: 569-578.
20. Lehtinen M. Vaccination against human
papillomaviruses shows great promise. Lancet 2004;
364: 1731-1732.
21. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human
papillomavirus-16 vaccine to prevent cervical
intraepithelial neoplasia: a randomised controlled trial.
Obstet Gynecol 2006; 107: 18-27.
22. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB,
Koutsky LA. Genital human papillomavirus infection:
incidence and risk factors in a cohort of female
university students. J Epidemiol 2003; 157: 218-226.
23. Garnett GP. Role of herd immunity in determining the
effect of vaccines against sexually transmitted disease. J
Infect Dis 2005; 191 (Suppl 1): S97-106.
24. Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2004.
Cancer incidence, mortality and prevalence worldwide.
IARC CancerBase No. 5, Version 2.0; IARC Press, Lyon,
2004.
25. Schiller JT, Nardelli-Haefliger D. Chapter 17: Second
generation HPV vaccines to prevent cervica l cancer.
Vaccine 2006; 24: 147-153.
26. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden
and management of non-cancerous HPV-related
conditions: HPV-6/11 disease.Vaccine 2006; 24: 35-41.
27. Stanley MA. Progress in prophylactic and therapeutic
vaccines for human papillomavirus infection. Exp Rev
Vaccines 2003; 2: 381-389.

Thank you for copying data from http://www.arastirmax.com